Clinical Trials Details

A051701 (Lymphoma)

A Randomized Phase II/III Study of Venetoclax (ABT199) plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Objective

This trial was temporarily closed to accrual on Aug. 2, 2021.

Clinical Trial Categories

  • Cancers and Other Neoplasms